Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PINK /
  3. GBIM.PINK

GlobeImmune Inc (GBIM PINK) stock market data APIs

$0.0002 0(0%) as of July 26, 2024
Price chart is built with Anychart

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado. GlobeImmune, Inc. is a subsidiary of NantCell, Inc.

GlobeImmune Inc Financial Data Overview

0.0002
0.0002
-
0.0002
0.0002
0.0002-0.0002
2 013 K
5 752 K
6 213 K
-0.15
-199.205
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'GBIM',
Type: 'Common Stock',
Name: 'GlobeImmune Inc',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000RC5CH3',
ISIN: NULL,
CUSIP: NULL,
CIK: '1245104',
EmployerIdNumber: '84-1353925',
FiscalYearEnd: 'December',
IPODate: '2014-07-02',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,
}

GlobeImmune Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 6 213 K
  • EBITDA -1 941 195
  • Earnings Per Share 0
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get GlobeImmune Inc Earnings via APIs

  • Latest Release 2016-05-12
  • EPS/Forecast NaN

Get GlobeImmune Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get GlobeImmune Inc latest news via APIs

GlobeImmune Announces Delisting and Deregistration of Common Stock

LOUISVILLE, CO--(Marketwired - July 05, 2016) - GlobeImmune, Inc. (NASDAQ: GBIM) On June 30, 2016, the board of directors (the "Board") of GlobeImmune, Inc. (the "Company") made a determination to del...
  • GLOBEIMMUNE

GlobeImmune Announces Updates and Financial Results for First Quarter 2016

LOUISVILLE, CO--(Marketwired - May 12, 2016) - GlobeImmune, Inc. (NASDAQ: GBIM) today provided an update on the Company's business and clinical programs and announced financial results for the first q...
  • GLOBEIMMUNE
Do you have any questions?
support@eodhistoricaldata.com